Soluble vascular endothelial growth factor receptor-1 contributes to the corneal antiangiogenic barrier

British Journal of Ophthalmology

Volumn 91, Issue 4, 2007, Pages 505-508

  Ambati, Balamurali K ^a   Patterson, Emory ^b   Jani, Pooja ^b   Jenkins, Crystal ^b   Higgins, Eric ^b   Singh, Nirbhai ^b   Suthar, Tushar ^b   Vira, Nehali ^b   Smith, Kimberly ^b   Caldwell, Ruth ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN RECEPTOR 1;

ADULT; AGED; ANIRIDIA; ARTICLE; BURN; CLINICAL ARTICLE; COGAN SYNDROME; CONTROLLED STUDY; CORNEA; CORNEA DISEASE; CORNEA INJURY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MALE; NEOVASCULARIZATION (PATHOLOGY); PEMPHIGOID; PRIORITY JOURNAL; PROTEIN EXPRESSION; VISION; WESTERN BLOTTING;

ADULT; AGED; ANIRIDIA; BLOTTING, WESTERN; BURNS, CHEMICAL; CORNEA; CORNEAL DISEASES; EPITHELIUM, CORNEAL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KERATITIS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; SOLUBILITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 34247220899     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2006.107417     Document Type: Article

References (15)

1. Epstein RJ, Stulting RD, Hendricks RL, et al. Corneal neovascularization. Cornea 1987;6:250-7.
2. Lai CM, Brankov M, Zaknich, et al. Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization. Hum Gene Ther 2001;12:1299-310.
3. Stechschulte SU, Joussen AM, von Recum HA, et al. Rapid ocular angiogenic control via naked DNA delivery to cornea. Invest Ophthalmol Vis Sci 2001;42:1975-9.
4. Ambati BK, Nozaki M, Singh N, et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature 2006;443:993-7.
5. Kong HL, Hecht D, Song W, et al. Regional suppression of tumor growth by secreted flt-1. Hum Gene Ther 1998;9:823-33.
6. O'Reilly M. Targeting multiple biological pathways as a strategy to improve the treatment of cancer. Clin Cancer Res 2002;8:3309- 10.
7. Chen H, Ikeda U, Shimpo M, et al. Inhibition of VEGF by transfection with sFLT. J Cardiovasc Pharmacol 2000;36:498-502.
8. Kendall RL, Thomas KA. Identification of a natural sFLT and its heterodimerization with KDR. Biochem Biophys Res Commun 1996;226:324-8.
9. Barleon B, Sozzani S, Zhou D, et al. Migration of human monocytes in response to VEGF is mediated via Flt-1. Blood 1996;87:3336-43.
10. Bainbridge JW, Mistry A, De Alwis M, et al. Inhibition of retinal neovascularization by gene transfer of soluble VEGF receptor sFlt-1. Gene Ther 2002;9:320-6.
11. He Y, Smith SK, Day KA, et al. Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity. Mol Endocrinol 1999;13:537-45.
12. Afuwape AO, Feldmann M, Paleolog EM. Adenoviral delivery of soluble VEGF receptor 1 (sFlt-1) abrogates disease activity in murine collagen-induced arthritis. Gene Ther 2003;10:1950-60.
13. Rota R, Riccioni T, Zaccarini M, et al. Marked inhibition of retinal neovascularization in rats following soluble-flt-1 gene transfer. J Gene Med 2004;6:992-1002.
14. Gehlbach P, Demetriades AM, Yamamoto S, et al. Periocular gene transfer of sFlt-1 suppresses ocular neovascularization and vascular endothelial growth factor-induced breakdown of the blood-retinal barrier. Hum Gene Ther 2003;14:129-41.
15. Ye C, Feng C, Wang S, et al. sFlt-1 gene therapy of follicular thyroid carcinoma. Endocrinology 2004;145:817-22.